leucovorin


Also found in: Dictionary, Acronyms, Encyclopedia, Wikipedia.
Related to leucovorin: methotrexate, Oxaliplatin, leucovorin rescue, Leucovorin calcium

leucovorin

 [loo″ko-vor´in]
leucovorin calcium the calcium salt of folinic acid, used as an antidote for folic acid antagonists, e.g., methotrexate, when there is need to reverse the toxic effects of the latter, in the treatment of megaloblastic anemias due to folic acid deficiency, and as an adjunct in the palliative treatment of colorectal carcinoma; administered orally, intramuscularly, or intravenously.

fo·lin·ic ac·id

(fō-lin'ik as'id),
1. The active form of folic acid that acts as a formyl group carrier in transformylation reactions; the calcium salt, leucovorin calcium, has therapeutic use.
2. The term is occasionally applied to other folates.

leucovorin

/leu·co·vo·rin/ (-vor´in) folinic acid; the calcium salt is used as an antidote for folic acid antagonists, e.g., methotrexate, and in the treatment of megaloblastic anemias due to folic acid deficiency and colorectal carcinoma.

leucovorin

(lo͞o′kə-vôr′ĭn, lo͞o-kŏv′ər-ĭn)
n.
A form of folic acid that is used to counteract the toxic effects of folic acid antagonists such as methotrexate and is also given as an adjuvant to increase the effectiveness of certain chemotherapy drugs, such as fluorouracil. It is usually given in the form of its calcium salt.

leucovorin

leucovorin

References in periodicals archive ?
He received 4 cycles of high-dose methotrexate (HDMTX) [3] with leucovorin rescue and 2 cycles of cisplatin and doxorubicin, which he tolerated well.
Physicians will be able to send a patient-specific prescription for the combination formulation of pyrimethamine and leucovorin to Imprimis, which is now a part of the Express Scripts pharmacy network.
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Rationale for treatment design: biochemical modulation of 5-Fluorouracil by leucovorin.
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
The randomized, controlled, 100-patient Phase 2 study is comparing the safety and efficacy of intravenous picoplatin given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen with oxaliplatin in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen.
Phase 1 study of picoplatin in combination with 5- fluorouracil and leucovorin as initial therapy in subjects with metastatic colorectal cancer.
The Company has been conducting clinical and pre-clinical studies with its lead product candidate, DAVANAT([R]), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin([R])).
Treatment with a regimen including CoFactor with 5-fluorouracil (5-FU) and capecitabine (Xeloda(R)), an oral prodrug of 5-FU, demonstrated superior inhibition of tumor growth and longer survival, with lower systemic toxicity compared with treatment groups containing leucovorin or capecitabine alone in a colorectal tumor model.
In addition, the results from our Phase II colorectal cancer trial for end-stage patients led us to initiate a Phase II trial to evaluate DAVANAT([R]) with AVASTIN([R]), 5-FU and leucovorin as a first line treatment for locally advanced, unresectable or metastatic colorectal cancer in patients unable to tolerate intensive chemotherapy.
The trial is designed to compare the safety and efficacy of 5-fluorouracil (5-FU) plus CoFactor(R) to 5-FU plus leucovorin in first line treatment of metastatic colorectal cancer.
When oxaliplatin was used along with the standard chemotherapy drugs 5-fluorouracil and leucovorin (the FOLFOX regimen), median survival was prolonged by more than 4 months and progression-free survival was prolonged by 2 months, compared with median survival in patients treated with the standard chemotherapy regimen of irinotecan, 5-FU, and leucovorin.